Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough

Rhea-AI Summary

Aldeyra Therapeutics to announce top-line results from Phase 2 clinical trial of ADX-629 in patients with chronic cough.

Positive

• Investors can expect positive news on the Phase 2 clinical trial results of ADX-629.
• Successful trial results could potentially boost Aldeyra Therapeutics' stock price.

Negative

• Negative results from the Phase 2 clinical trial of ADX-629 may negatively impact Aldeyra Therapeutics' stock price.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑629 in patients with chronic cough.

The dial-in numbers are (888) 415‑4305 for domestic callers and (646) 960‑0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease (under U.S. Food and Drug Administration New Drug Application Review) and allergic conjunctivitis, and ADX‑2191, a novel formulation of intravitreal methotrexate for the potential treatment of proliferative vitreoretinopathy and retinitis pigmentosa.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230626532832/en/

Investors & Media:

David Burke

Tel: (917) 618-2651

investorrelations@aldeyra.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When will Aldeyra Therapeutics announce the top-line results from the Phase 2 clinical trial?

Aldeyra Therapeutics will announce the top-line results on Tuesday, June 27, 2023.

What is the purpose of the Phase 2 clinical trial of ADX-629?

The Phase 2 clinical trial aims to evaluate the efficacy of ADX-629 in patients with chronic cough.

Where can I access the webcast and conference call?

The webcast and conference call can be accessed through the 'Investors & Media' section of Aldeyra's website at ir.aldeyra.com.

How long will the event be archived on Aldeyra's website?

The event will be archived on Aldeyra's website for 90 days.